01:11
them so um I guess to start it off I
01:14
just wanted to say to talk about the
01:18
symposium so obviously we had the OMF
01:20
third annual symposium that was early
01:25
September September the 7th I think
01:27
wasn't it right and I just wanted your
01:31
thoughts on how it all went really just
01:33
just general just general force any
01:36
signs that were different to last year
01:38
exception like that we're making
01:44
progress we had some new people gift
01:47
talks I did bring in some engineers to
01:55
work on some of the problems and now
01:58
we're trying to sort out the the
02:01
differences that they find versus the
02:03
differences that we found earlier and so
02:06
we're we're in the midst of exploring
02:09
that earlier we found deformability and
02:13
the new device doesn't see it so we're
02:17
looking at the differences that were
02:18
present one of our concern is that
02:22
they're putting the Ritz Hills in two
02:25
phosphate buffered saline and it may
02:29
have to stay in the plasma so they're
02:32
setting up new experiments to see if
02:34
that will make a difference we're
02:35
looking at the just a detail sometimes
02:38
of these techniques very subtle things
02:41
that you do make it work or not work and
02:44
you don't actually know why yeah it is a
02:47
difficult time to transfer the
02:50
technology I've got a lot of experience
02:53
that and I'm also a lot of companies
02:54
have experience or the technology and
03:00
they try to give everything in all the
03:02
details but there are certain things
03:04
that change yeah I think that's a common
03:11
problem but I've told the community that
03:16
when we have these symposium we're going
03:17
to give you the very latest up-to-date
03:20
things that we're doing this is what's
03:22
happening in the lab right now and sort
03:25
of full disclosure and we're not waiting
03:29
until we have a publication out and then
03:31
we can tell you about the publication in
03:36
my experience doing these complex things
03:38
it usually takes two to three years
03:41
before when you start something before
03:44
you actually have the paper up I'm my
03:47
feeling is that just way too long and
03:51
NIH likes it likes the papers I do too
03:55
and I think we can communicate things
03:57
much yeah I remember you I think saying
04:02
last time or maybe when we've talked off
04:06
like when it's not being recorded about
04:08
how I mean it's quite obvious when you
04:12
think about it but it's one of those
04:14
things that sometimes you do have to
04:16
think about it is like for example the
04:20
media that they're like the medium sorry
04:23
that the cells are in can really affect
04:27
results of the experiments and sometimes
04:30
things can be assumed about the media
04:33
medium like what Evers added in as a
04:35
buffer etc or anything like that and
04:38
that may have changed from one year to
04:41
the next and that can actually obviously
04:44
like just you're talking about can it
04:46
affect the results and it's it's quite a
04:49
hard thing to pinpoint down because it's
04:50
obviously something that could go
04:52
unnoticed if you weren't paying close
04:55
attention so if we actually do develop a
05:02
technology thing we want to export we
05:05
often do a lot of troubleshooting we
05:08
look at changes in the protocol changes
05:13
in the concentrations to see if there's
05:15
anything that's very sensitive to the
05:17
technology yes we haven't begun to do
05:20
that with the metabolic trap and I'm
05:24
sorry not the yeah we're worried that it
05:33
probably does have some sensitivities
05:36
but we'll figure that out okay the
05:43
problem is you may pick a condition that
05:44
is just right at the edge of having it
05:48
work and if you make up the solutions
05:50
although incorrect and it doesn't work
05:54
we want to find out if that's going to
05:56
be the case but right now it's not ready
05:59
for export but we're working on trying
06:02
to get it so at least it could be
06:03
exported to the same to the community
06:05
that would be the first pass because
06:08
they'll be little easier for them to
06:11
take on something technically quite
06:13
difficult and then later you go to
06:17
testing laboratories and they usually is
06:21
fairly inexperienced people it has to be
06:27
very routine and simple yes I mean that
06:32
actually follows on quite nicely because
06:34
by far and away I'll ask the questions
06:38
like from from the other patients at the
06:40
end but
06:41
fine away the biggest question by just
06:45
by by a magnitude of I don't know why
06:48
was basically what's in the blood or
06:52
what isn't in the blood or what thing
06:54
what multiple things are in the blood to
06:56
cause this impedance signal I think
06:58
people were and obviously myself and
07:02
everyone is because it sounds very
07:04
simple it sounds like a very simple
07:06
thing to you know something's in the
07:08
blood what's causing this thing it's and
07:11
it's obviously incredibly kind of
07:14
symbolic in a way because I think
07:16
there's been some diagrams going around
07:18
on Twitter that say like any cells in
07:22
healthy patients blood and they're okay
07:25
and then you have hope I've got this to
07:27
the right way around with my cognition
07:28
but then you've got obviously healthy
07:32
cells in any patient blood and they have
07:35
that same or very similar impedance
07:37
measurement I don't know if you can
07:40
clarify that's actually fairly
07:42
interesting because my patient and then
07:48
take the cells out and put it into
07:50
healthy plasma lose the signal so that
07:55
means that the plasma from the patients
07:58
have to be in contact with the cell at
08:01
all times
08:02
yes it's not likely you treat the cells
08:06
and now they're stuck in this pattern
08:08
they go out of that pattern very quickly
08:11
which raises some of the issues with
08:13
people using a seahorse instrument and
08:15
trying to compare it because the
08:18
seahorse instrument no it's routinely
08:19
done is not done in plasma it's done in
08:22
buffer they may not see what we're
08:27
seeing because of that we've tried to
08:31
run it in very a very small amount of
08:39
that's why they run buffer okay can can
08:43
you can you just give a I guess a brief
08:46
kind of explanation of why it's not
08:48
quite so simple that it's just something
08:50
in the blood why it's quite hard to find
08:53
out what that may be
08:54
or what those things may be I think we
08:58
can figure it out it's just very
09:01
difficult with our current set up
09:05
because we have a fairly thirty thousand
09:09
dollar instrument that can only do two
09:11
samples at a time and it takes several
09:14
hours to do the setup and run and what
09:18
you would be doing is fractionating the
09:21
plasma with different techniques and now
09:24
you would say fractionated into ten
09:26
fractions but now you're going to
09:27
measure all ten fractions so the problem
09:31
is when we could do two of the finishes
09:33
and then we could get a patient to come
09:36
in the next day cuz they should we
09:38
shouldn't ask the same patient to get
09:39
blood and so we have a different patient
09:42
to do another two fractions how do we
09:46
interpret that it's just not going to do
09:48
this experiment and it would take a lot
09:51
of time and effort the way to do this is
09:53
to change the electronics and the way
09:56
the chips are also all done and be able
09:59
to hundred at a time so it doesn't take
10:04
much blood for this one patient donation
10:08
would be able to do a hundred samples
10:09
and so now you could do the
10:12
fractionation and back do quite a few
10:15
different fractionation so I wrote it
10:17
all at the same time so that's a better
10:20
way to figure this out it's a kind of
10:23
funding and scalability issue which are
10:26
kind of intrinsically linked obviously
10:35
okay that it will because he's a young
10:39
investigator and there's no different
10:41
preference for that but the proposal is
10:43
pretty complicated in the Sin City has
10:46
to rebuild these electronics for this
10:56
okay that's interesting that's obviously
11:00
yeah brahim is obviously the person who
11:04
is he's the engineer behind the
11:08
cell impedance device isn't he no no
11:15
have I got that completely wrong she
11:21
started in San Jose State that's
11:23
continuing but so Rahim
11:28
so the initial impedance device was that
11:31
not cannot constructed by Rahim no yes
11:54
yeah he does come up once a week but he
12:01
just delivered on Friday a new batch of
12:04
chips that was his prime
12:06
start at the new location getting a
12:11
graduate student getting a graduate
12:13
student trained to fabricate we haven't
12:16
yet tested them so I'm hoping they will
12:18
work yeah I think I don't then they have
12:21
to start over make another batch but
12:24
that new batch will help us do a lot of
12:27
experiments we'll do the ones that where
12:29
we can get a good where we can get a
12:30
good experiment just using one or two
12:33
chips yes with our current with our
12:36
current device there's a number of
12:37
things that we can do okay that make
12:41
sense I thought I was going mad there
12:42
for a second I'm glad that I yeah that
12:45
makes sense now
12:45
um yeah okay so another thing that was I
12:52
think this was with from upsala the
12:57
center there that's that you guys are
13:00
working with because now you've
13:01
obviously got Stanford you've got
13:03
Harvard and you've got Uppsala
13:06
University yes so you've got three
13:10
centers which are working together which
13:13
i think is quite incredible really and a
13:16
huge step forwards and one of the things
13:18
i picked up from that was really
13:21
interesting
13:23
that I think it was it was them that
13:26
we're doing this which was the
13:29
proteomics of neuro inflammation markers
13:32
in patients Auto antibodies autoimmunity
13:36
and steroid and thyroid hormone
13:40
regulation there I think they're also
13:44
doing
13:44
microglia imaging I'm reading this off
13:47
my little note list the country so our
13:57
working group okay and we do have to
14:01
talk with him because he's doing some
14:02
things that we're also doing and we just
14:06
don't want duplication of effort
14:08
validation of results is valuable so it
14:12
has to be along those lines and but also
14:16
we haven't done any as final thought and
14:19
he said an expert in that as well
14:21
so yeah there are a number of
14:23
experiments that I think should be done
14:25
well either ship the technology and to
14:28
him or evil ships ship samples to us
14:31
probably the shipping to us will work
14:33
because most of these I'd like to look
14:37
at for any presence of any viruses or a
14:40
poor bacteria we would do that by
14:45
looking for DNA its DNA is very stable
14:47
can be frozen no it's not a problem they
14:51
will send in freezing canisters okay
15:00
well they will the freezing of I mean
15:03
obviously it will in some way but were
15:05
the for that I'm presuming obviously for
15:08
the purpose of what you want it for the
15:09
freezing of the samples won't affect the
15:12
results in terms of because obviously I
15:15
know for certain things you need fresh
15:18
plasma for doing something sort of
15:22
biological which is a biological assay
15:26
okay yeah freezing can be a real problem
15:29
we have good results with freezing you
15:32
still get a weak signal but it's
15:35
it's not trustworthy okay so we don't
15:38
want to use frozen samples but DNA
15:41
analysis is we have a lot of expertise
15:43
not the world has a lot of experience
15:46
not just us yeah about handling do DNA
15:50
is very stable but RNA is also stable so
15:53
we will look at the RNA and the DNA yeah
15:56
just something that needs to be done we
15:58
have the technology to readily do it so
16:01
on that front
16:04
we're setting up to do RNA analysis so
16:07
we can look at the RNA viruses and
16:11
that's a project that isn't funded in
16:14
fact none of the stuff that kid Dongshan
16:16
has been doing with DNA analysis and
16:18
looking for viruses is a specific
16:23
project that's funded uh-huh
16:26
and this is a good time to make
16:28
donations because open medicine
16:31
foundation is now having their triple
16:33
Tuesday that makes your your your
16:43
donation more effective I wish for such
16:46
work so expensive but it is and we are
16:52
putting in another grant on the 11th of
16:55
November and we're gonna have at least
16:59
one or two grants every every NIH round
17:02
okay and the best way if they don't want
17:06
us to keep so many grants is to give us
17:08
a few yeah I mean again that's yeah it's
17:13
triple Tuesday at the moment so
17:15
obviously every if someone gives one
17:19
dollar
17:19
err OMF get three dollars if someone
17:21
gives five dollars OMF get 15 etc and so
17:24
on and I think the aim this time is to
17:28
to raise a million dollars which is
17:30
obviously a lot of money a lot of money
17:34
but it's it's also at the same time it's
17:36
quite easy I think to forget that so
17:39
much work so far has been self funded or
17:42
funded by OMF standards and I was
17:46
looking on their website the other day
17:48
obviously
17:48
patient advocate and a volunteer but I'm
17:52
a severe patient first and foremost so
17:55
I'm interested in the organization and
17:58
how much money people of raising and how
18:01
much money that organization is raising
18:02
and I think it would said something
18:04
close to 20 million in five years maybe
18:08
which i think is quite astounding amount
18:11
of money and it's enabled you you guys
18:14
and other now the other
18:18
Harvard and Uppsala to be able to
18:21
continue researching so with triple
18:24
Tuesday obviously being a focus at the
18:27
moment that money goes so much further
18:30
and I guess we're very fortunate in to
18:34
have those those donors who were willing
18:36
to to match and provide those extra
18:39
funds so hopefully if people support the
18:44
cause don't though they'll donate and
18:48
we'll get there faster until any NIH
18:52
pull their finger out basically so yes
18:59
we have a we're setting up into
19:02
collaboration which is an area that I've
19:05
been wanting to get into and that is
19:06
he's a neurologist at Stanford when he's
19:12
particularly of interest to us he has a
19:14
lot of experience with the effect of
19:18
plasma and materials in the plasma that
19:22
affects the brain okay since we see
19:26
affects the plasma we would like to try
19:30
to explore that and he's very interested
19:32
in doing it we don't really have a
19:34
budget for that we don't know how
19:36
expensive it's going to be that
19:39
hopefully will be another project that
19:42
could be very beneficial we don't have
19:45
to learn a neurological effects and it
19:48
would be wonderful if some of that could
19:50
be modified by things in the plasma
19:53
so it's either something bad in the
19:55
plasma that's making things worse or it
19:58
could be the absence of something good
19:59
both of those were that yeah that leads
20:05
really nicely onto actually one of the
20:09
things I'd noted down which is one of
20:12
the compounds that was really low in
20:14
patience I hope I'm pronouncing this
20:16
right I have read this some of the about
20:18
this compound before but it's in Dali
20:21
propria Nate yes it's not a very
20:27
complicated compound you can actually
20:29
buy it but it's not not clear that it's
20:31
safe to take good because it's made by
20:33
chemical manufacturer yeah
20:36
and there is a there is a company that's
20:39
exploring that as a as a supplement for
20:46
brain protection it's in clinical trials
20:50
at the moment the major thing we need to
20:53
find out is whether the preparations
20:56
they've made are safe and if it is then
20:59
we would like to try to do a
21:01
collaboration with them we haven't
21:03
talked to them yet they have to get
21:06
results before we can do that but we're
21:08
very willing to work with industry as
21:10
well as academics yeah I mean reading
21:17
about it was very interesting because
21:18
obviously just as a bit of background if
21:21
people aren't familiar with that
21:23
compound it's it's a it's a neuro
21:27
protect protective made by species of
21:30
Clostridium bacteria in the gut isn't it
21:33
and so with all the gut issues we have
21:37
and some of the findings I think by
21:40
Hanson and just I mean there's a lot of
21:42
findings now evidence of dysbiosis and
21:46
that various things like that I think
21:49
it's a very interesting compound in
21:54
itself and I think it's it's one I might
21:56
be wrong on this and you can correct me
21:59
but I think it's a compound similar to
22:01
melatonin in the sense that I don't I
22:04
think it's an antioxidant but I don't
22:06
think it's first of all a pro-oxidant I
22:09
think it's just an ant like an
22:11
antioxidant like an innate aunty on
22:13
and it functions as an innate
22:15
antioxidant watching Bill effects yeah
22:24
explain why fecal transplants or helping
22:28
people yes because although severe
22:32
patients have low levels yeah by putting
22:36
the organism back in what the fecal
22:39
transplants going to be done correctly
22:40
because if it's a close-fitting miss
22:43
killed by oxygen so I can imagine some
22:46
time not working because you exposed the
22:50
transplant to too much oxygen so it
22:54
would be it might be simpler and cheaper
22:57
as you simply get the compound and take
23:01
it as a pill since it's made by the
23:03
bacteria in the gut putting it back the
23:05
compound and the gut should be fine
23:08
isn't going to get destroyed because
23:10
it's not destroyed already yeah that's
23:15
gonna take a while before that's
23:18
permanent but we are working on that so
23:22
right now we're putting a little bit of
23:24
a heavy focus on kind of trying to come
23:26
up with some ideas that could help the
23:29
patients as we try to figure out what's
23:31
causing the disease yeah okay that's
23:35
yeah that's really interesting this one
23:37
that really kind of stood out to me I
23:39
know it had been mentioned briefly
23:41
before but it was mentioned again and
23:43
that I found that I personally I found
23:46
it very interesting with having a lot of
23:48
guys shoes myself and talking to other
23:50
patients yeah I found that one very
23:53
interesting
pt3 [includes stuff re CCI, and mark davis and t-cells]
23:58
I mean it's a big thing recently I think
24:03
because of a Jen Brea that a guy called
24:10
Jeff who has a website called mechanical
24:13
basis and also another patient called
24:15
Matty is CCI so crania cervical
24:19
instability which I'm going to do a very
24:24
bad job of explaining because of having
24:26
a foggy brain but
24:27
it's essentially the laxity of ligaments
24:32
and pathology of pathology of basically
24:41
connective tissue and ligaments
24:42
affecting the brain stem and various
24:47
various organs in in that area that's
24:51
not the best explanation at all but I
24:55
think a lot of people know about it
24:57
already and it's it's obviously if if
25:02
the brain stem is compressed various
25:05
yeah I mean that's gonna be truly not
25:09
very good for obvious reasons but having
25:14
heard of these like success stories that
25:18
gem Bayer has had and Jeff and Matt
25:22
Matti I just wonder what your thoughts
25:25
on CCI are obviously is it from a
25:29
patient perspective I kind of want every
25:31
I mean these these stories are quite
25:32
incredible to me I don't I don't
25:37
understand in terms of in terms of
25:41
there's there's some theories out there
25:43
and I know Jim Bray is working on some
25:45
and some have been discussed on forums
25:47
before on why the issues have been
25:51
alleviated for some people who have had
25:54
surgery it's a small number at the
25:56
moment but it's fascinating to me that
26:00
those that someone diagnosed with ICC
26:05
mecfs fulfilling all of the criteria
26:08
having essentially a structural issue
26:11
resolving most of their symptoms for -
26:14
for the two people I know and I think
26:18
the other person is resolved they've
26:21
gone from severe to moderate which is a
26:23
huge step up I just wondered your
26:28
thoughts on if what your thoughts on CCI
26:31
are if you're investigating it and yeah
26:36
just your general
26:38
ponderings wrong well I talked to a
26:43
number of physicians that specialize in
26:45
mecfs their thoughts are that it's
26:51
probably a fraction of the patients
26:54
really have that problem but it's
26:56
probably not all and so that's one of
26:59
the confounding issues then if it's not
27:03
all and why doesn't what are the two
27:05
populations seem to be exactly the same
27:07
yeah so that's a bit of an unexplained
27:11
one of the things that is also
27:13
consistent with the CC is that we find
27:18
that in the severe patients some of the
27:22
highest metabolites in the blood are
27:24
lysine and hydroxyproline those are
27:29
major constituents of of the connective
27:32
tissue in the collagen yeah that's that
27:35
would be consistent with any degradation
27:37
of the collagen that's not proof that
27:40
that's the case because it could be
27:43
almost the opposite that because the
27:46
collagen is weak
27:48
the body is actually revving up the
27:51
production of those molecules yes they
27:54
used a new synthesis however it just
27:59
says that that is consistent with
28:01
connective tissue issues we see the
28:05
building blocks higher we have to sort
28:08
that out we have some looking at we're
28:12
now doing a lot of pathway analysis a
28:14
lot of fair is really good at there yeah
28:16
we're measuring a number of things in
28:19
the pathways and are finding places
28:22
where we could stimulate the degradation
28:25
or inhibit the synthesis you know that's
28:29
going to be explored a lot more so we do
28:33
have a pretty big effort on pathway
28:36
analysis and we're trying to get all the
28:39
different components in the pathways to
28:42
be quantitated that's going to be
28:45
expensive because many of them nobody
28:48
does it and so we're going to have to
28:49
set up special
28:51
tools yeah yeah yeah I mean you
28:57
literally asked answered my next
28:58
question was the link about EDS
29:01
hydroxyproline excretion being high and
29:05
possibly indicating the degradation of
29:08
collagen so that's really helpful I
29:12
think I don't know if this is still the
29:14
case but I did read I think it popped up
29:19
somewhere that you guys were looking for
29:21
people before the people who were
29:24
potentially having CC eye surgery and
29:28
after blood after four blood samples is
29:31
that still okay and we'll do that look
29:34
at the metabolomic says we'll get their
29:37
sequence and we'll do the nano needle
29:39
assays I don't know the timing of that
29:43
why we have a found a few patients some
29:46
of them are you know local so getting
29:51
their sample may be a little tricky but
29:55
we are capable of traveling to patients
29:58
we've done that a couple of times when
30:01
we've actually gone to patients and we
30:05
have most of the equipment that we need
30:07
to process a bit portable yeah thinking
30:11
of equipping a van with all the
30:16
equipment that we need so that we can
30:18
actually go patients that are unable to
30:23
come to us yeah all right that sounds
30:30
that sounds fantastic
30:32
very cool equipping a van appealing to
30:37
appeal to my geek side yeah so okay so
30:46
is that just to clarify is that still
30:49
ongoing
30:49
are you still looking for potential
30:52
patients is that something that if
30:54
someone's having that operation for
30:56
whatever reason you still want you would
31:00
want to be in contact with them yes okay
31:05
you know what is doing this in Europe
31:07
are gonna be much more difficult yeah
31:11
the closer they are to us the less
31:14
expensive it will be
31:15
yeah sometimes those patients actually
31:18
come to the Bay Area because we know a
31:20
number of physicians that specialize in
31:23
mecfs
31:24
so yeah they come here to see the doctor
31:30
maybe before work yes
31:35
yeah that makes sense okay that's that's
31:39
good
31:41
so next mark Davis and T cells so that
31:49
was one thing that was in the symposium
31:54
and patients were also came up a lot in
31:58
for patient questions basically people
32:01
wanted to know the progress but
32:03
obviously I think in the symposium you
32:05
mentioned or it was mentioned sorry that
32:09
the T cells the T cells the immune T
32:13
cells were reacting but you've now since
32:15
found out they weren't reacting anymore
32:17
than control patient cells were but you
32:22
don't know whether they're reacting to
32:23
something different and that's what
32:25
you're finding trying to find out next I
32:27
don't know if that's okay so he wasn't
32:35
able to come to the to be at this
32:38
symposium the work isn't complete my
32:45
understanding of making some progress in
32:47
that area to find out what they're
32:49
reacting to the initial thing that
32:53
started this whole project is we had a
32:56
fairly small number of patients and
32:58
controls and the patients had a lot more
33:03
reaction and the healthy controls since
33:06
then we've done a lot a lot of patience
33:08
and a lot of healthy controls and now
33:12
the difference doesn't look so great we
33:13
find some healthy controls that have a
33:16
lot of reaction
33:17
maybe they just had a cold or something
33:20
and then the recent past and we've also
33:24
found patients that have almost no
33:26
t-cell reactivity so the level of
33:30
reactivity is not going to be a good
33:32
indicator so the question then is that's
33:35
why we have mark working on this project
33:37
to look at what may be what they're
33:40
reacting to it's very important to try
33:43
to figure out if there is a pathogen
33:46
because in most cases if there is a
33:48
passage and we know how to get rid of it
33:51
yes and then we know how to an assay to
33:57
see if it is gone so that's why it's so
34:00
important to keep searching for a
34:02
pathogen all the indicators are would be
34:07
consistent with a presence of a
34:09
persistent pathogen just name one the
34:15
disease sleeping sickness in Africa if
34:18
you look at the symptoms that the
34:19
patients have they're pretty
34:21
indistinguishable from any CFS
34:24
they call a sleeping sickness because
34:27
they switch their light day/night cycle
34:31
which a lot of patients do as well yeah
34:35
I look for in it's a Trypanosoma and
34:38
we've searched a number of samples for
34:42
Trypanosoma and we're doing a broad
34:47
search for trypanosomes all the ones
34:48
that have been discovered so far looking
34:51
for things that are conserved sequences
34:53
in them so that even if it were an
34:56
unrelated to been its own we do see we
35:02
don't just do one probe we do eight to
35:05
fourteen different probes each organism
35:08
so all we need is one of them to work so
35:12
it's a pretty good assay it may not be a
35:18
trousseau yes I mean I one thing that
35:22
that's often brought up and is I'm
35:25
really interested in to his office is
35:28
enteroviruses
35:31
and things like Coxsackie that may
35:35
Harbor themselves in the gut and various
35:37
things like that but again if you're
35:39
doing RNA analysis that should be taken
35:45
care of well it should be it's a little
35:49
more complicated because RNA is not
35:51
nearly stable is d anything yeah we hang
35:54
around for nearly as long and we'll have
35:57
to develop some good healthy you know
35:59
some good controls on that there is some
36:02
experience in it so it's not without any
36:05
experience you certainly can find that
36:08
when someone has an infection with those
36:11
viruses so we'll do all those kind of
36:19
controls to make sure that where we
36:21
actually can't see that we're also you
36:24
know we also take seriously with
36:26
patients right into whistle what about
36:28
this or what about that
36:30
of course many patients have worried
36:32
about the intra viruses and we'd
36:35
certainly take that seriously that needs
36:38
to be looked at it's just the
36:39
technicality of doing a good job of it
36:43
yes so that there has been a patient
36:46
that has mentioned possibility of a
36:49
nematode that's a bit of a tough one
36:56
because that's very difficult to get the
36:58
DNA out that we know how to do that I
37:02
think getting them we will probably
37:03
explore that as well anything that's
37:07
kind of as an organism could be the
37:10
cause of this yeah that makes sense
37:16
that's good to hear searching we really
37:28
need to publish the negative results
37:30
somehow because it's important to know
37:32
what you look for yeah yeah and the
37:37
methods involved as well it's just it's
37:39
just so important to record
37:42
to make sure that that's not the cause
37:45
because you could probably cure it if
37:47
you think if they figure that out yeah
37:50
and if you couldn't it would put a big
37:51
driving force for industries and develop
37:54
drugs that would kill those organisms
37:56
yeah yeah um I think you also it was
38:02
also mentioned that you were testing for
38:03
mycotoxins and mold I think that you I
38:07
think you might know a guy called Erik
38:09
Johnson
38:10
yeah he's fair visited here we've had
38:15
people go to his we haven't started
38:20
anything I gotta I gotta find the right
38:22
people sometimes you can't just start a
38:26
project you really have to have somebody
38:28
that's really an expert in that area
38:32
because you don't want to reinvent all
38:35
the different methods and so forth that
38:37
are out there it's a lot cheaper and
38:40
faster if you can find the right person
38:42
so we person for for doing that and
38:48
that's a project that needs funding as
38:50
well yeah I was gonna say it can't just
38:53
depend on any age because they will not
38:55
fund anything that you haven't already
38:57
done yes it creates a huge problem when
39:02
you want to start something new they're
39:04
just there's no mechanism for doing it
39:07
at NIH that's why people when they start
39:10
a research program often do that same
39:12
level research their entire career
39:14
because that's so difficult to switch
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
